Read through the scenario below, think about what you would do and then check our expert advice to see if we agree.
A growing number of my patients are using GLP-1s for weight loss, and they are concerned about the risks to their vision. What advice should I give?
With more patients using Glucagon-like peptide-1 (GLP-1) medicines such as Wegovy, Ozempic, Mounjaro and Rybelsus, you may be hearing increasing concerns about their potential impact on vision.
This month, we're here to support you with evidence-based guidance, helping you give clear, balanced and reassuring advice in practice. While these treatments offer important benefits, emerging evidence suggests a very rare link to ocular events, including Non-arteritic Anterior Ischaemic Optic Neuropathy (NAION).
So, what should you tell your patients?
Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.
These cases are based on member calls or emails made to our clinical advisers. We do not share any personal details of those seeking advice and have modified the cases to ensure confidentiality. This clinical file is intended to help members understand how the existing Guidance for Professional Practice (GfPP) can be applied in everyday practice, this clinical file is not intended as supplementary or additional annex to the GfPP.
If you have a question or need advice, you can contact the College's clinical advisers during office hours.